| Management target | Revenue 9.0% FY27 |
|---|
| Revenue growth | 10.1% YoY growth; strong India and Specialty, soft US generics. |
|---|---|
| Margins | Gross margin 80.5%; EBITDA 28.9%, pressured by launch costs. |
| Demand visibility | Strong specialty uptake and stable chronic demand in India. |
| Management confidence | Confident in Specialty and India; cautious on US generic competition. |
Growth
Revenue grew 10.1% YoY to ₹151,836 million, supported by 16% growth in India formulations and a 12.8% rise in specialty sales.
Outlook
Management maintains high single-digit growth guidance for FY27 despite the strong Q1 start and pending Organon acquisition closure.
Risks
US generic revenue declined 9.7% due to Lenalidomide erosion and generic competition. Higher tax rates and acquisition costs impact net margins.
Last quarter's promises, checked
Delivered
- Guided high single-digit top-line growth → delivered 10.1% (= BEAT)
- Guided R&D spend 6-7% of sales → delivered 5.4% (= BEAT)
- Guided effective tax rate ~25% → delivered 22.3% (= BEAT)
Partly delivered
- Guided Organon acquisition closure Q4 FY27 → On track, filings in progress (= PARTIAL)
Missed
- Guided US business growth → delivered -9.7% revenue decline (= MISS)
Earnings Call Transcript filed with NSE, NSE: SUNPHARMA. Summary written with AI assistance from the document.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,852.20
- Market cap
- ₹4,44,405 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 36.7×Sector 50.4×
- Promoter holding
- 54.48%+0.00% QoQ
- FII holding
- 14.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Promoter Reclassification
Sun Pharmaceutical has received shareholder approval to reclassify specific persons from the 'Promoter Group' to the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharmaceutical Industries Investor Presentation: Key Takeaways
Sun Pharma reports Q1FY27 data showing diversified revenue of Rs 582 Bn for FY26. Key strategy remains scaling Innovative Medicines (22% of sales) and maintaining India market leadership (8.5% share).
Sun Pharmaceutical Industries Legal & Regulatory
Sun Pharma's subsidiaries signed a settlement agreement resolving antitrust litigation in the U.S. for a confidential amount, without any admission of wrongdoing.
Sun Pharmaceutical Industries Merger & Restructuring Worth ₹9.5 Cr
Sun Pharma incorporates a new treasury subsidiary in GIFT City, Gandhinagar. Initial equity subscription is approximately ₹9.50 Crore for group treasury operations.
- Value
- ₹9.50 Cr
Sun Pharmaceutical Industries Credit Rating
Sun Pharma has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P. These investment-grade ratings reflect the company's strong financial profile.
Sun Pharmaceutical Industries Investor Presentation: Key Takeaways
Sun Pharma reported Q1FY27 revenue growth of 10.1% YoY to INR 151,836 million with an EBITDA margin of 28.9%. Growth was driven by Global Innovative Medicines and India formulations.
- Call
- Guides 9% growth